The DOI matches its Crossref record; 309 of the 309 references it cites were found in a registry or an index.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Open accessAbstract
BACKGROUND: Cardiovascular disease (CVD) is the most frequent cause of death in people with early stages of chronic kidney disease (CKD), for whom the absolute risk of cardiovascular events is similar to people who have existing coronary artery disease. This is an update of a review published in 2009, and includes evidence from 27 new studies (25,068 participants) in addition to the 26 studies (20,324 participants) assessed previously; and excludes three previously included studies (107 participants). This updated review includes 50 studies (45,285 participants); of these 38 (37,274 participants) were meta-analysed. OBJECTIVES: To evaluate the benefits (such as reductions in all-cause and cardiovascular mortality, major cardiovascular events, MI and stroke; and slow progression of CKD to end-stage kidney disease (ESKD)) and harms (muscle and liver dysfunction, withdrawal, and cancer) of statins compared with placebo, no treatment, standard care or another statin in adults with CKD who were not on dialysis. SEARCH METHODS: We searched the Cochrane Renal Group's Specialised Register to 5 June 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care, or other statins, on mortality, cardiovascular events, kidney function, toxicity, and lipid levels in adults with CKD not on dialysis were the focus of our literature searches. DATA COLLECTION AND ANALYSIS: Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were expressed as mean difference (MD) for continuous outcomes (lipids, creatinine clearance and proteinuria) and risk ratio (RR) for dichotomous outcomes (major cardiovascular events, all-cause mortality, cardiovascular mortality, fatal or non-fatal myocardial infarction (MI), fatal or non-fatal stroke, ESKD, elevated liver enzymes, rhabdomyolysis, cancer and withdrawal rates) with 95% confidence intervals (CI). MAIN RESULTS: We included 50 studies (45,285 participants): 47 studies (39,820 participants) compared statins with placebo or no treatment and three studies (5547 participants) compared two different statin regimens in adults with CKD who were not yet on dialysis. We were able to meta-analyse 38 studies (37,274 participants).The risk of bias in the included studies was high. Seven studies comparing statins with placebo or no treatment had lower risk of bias overall; and were conducted according to published protocols, outcomes were adjudicated by a committee, specified outcomes were reported, and analyses were conducted using intention-to-treat methods. In placebo or no treatment controlled studies, adverse events were reported in 32 studies (68%) and systematically evaluated in 16 studies (34%).Compared with placebo, statin therapy consistently prevented major cardiovascular events (13 studies, 36,033 participants; RR 0.72, 95% CI 0.66 to 0.79), all-cause mortality (10 studies, 28,276 participants; RR 0.79, 95% CI 0.69 to 0.91), cardiovascular death (7 studies, 19,059 participants; RR 0.77, 95% CI 0.69 to 0.87) and MI (8 studies, 9018 participants; RR 0.55, 95% CI 0.42 to 0.72). Statins had uncertain effects on stroke (5 studies, 8658 participants; RR 0.62, 95% CI 0.35 to 1.12).Potential harms from statin therapy were limited by lack of systematic reporting and were uncertain in analyses that had few events: elevated creatine kinase (7 studies, 4514 participants; RR 0.84, 95% CI 0.20 to 3.48), liver function abnormalities (7 studies, RR 0.76, 95% CI 0.39 to 1.50), withdrawal due to adverse events (13 studies, 4219 participants; RR 1.16, 95% CI 0.84 to 1.60), and cancer (2 studies, 5581 participants; RR 1.03, 95% CI 0.82 to 130).Statins had uncertain effects on progression of CKD. Data for relative effects of intensive cholesterol lowering in people with early stages of kidney disease were sparse. Statins clearly reduced risks of death, major cardiovascular events, and MI in people with CKD who did not have CVD at baseline (primary prevention). AUTHORS' CONCLUSIONS: Statins consistently lower death and major cardiovascular events by 20% in people with CKD not requiring dialysis. Statin-related effects on stroke and kidney function were found to be uncertain and adverse effects of treatment are incompletely understood. Statins have an important role in primary prevention of cardiovascular events and mortality in people who have CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–309 of 309
Zito, F., Lowe, G. D. O., Rumley, A., McMahon, A. D., & Humphries, S. E. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00196-x · Cited by 63
Verma, A. K., Ranganna, K. M., Reddy, R. S., Verma, M., & Gordon, N. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.074 · Cited by 63
Screening experience and baseline characteristics in the West of Scotland coronary prevention study
* (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80135-0 · Cited by 63
Kendrick, J., Shlipak, M. G., Targher, G., Cook, T. J., Lindenfeld, J. M., & Chonchol, M. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.09.020 · Cited by 62
Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?
Campese, V. M., Nadim, M. K., & Epstein, M. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110958 · Cited by 61
Fellström, B., Holdaas, H., Jardine, A. G., Rose, H., Schmieder, R. E., Wilpshaar, W., & Zannad, F. M. (2007) · Kidney & Blood Pressure Research · doi:10.1159/000106803 · Cited by 60
A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD
Dogra, G. K., Irish, A. B., Chan, D. C., & Watts, G. F. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.03.003 · Cited by 59
Simes, R. J., & The PPP and CTT Investigators (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80482-2 · Cited by 59
The west of Scotland Coronary Prevention study: A trial of cholesterol reduction in scottish men
Shepherd, J. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80480-9 · Cited by 58
Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study: Table 1
Batty, G. D., Wang, Y., Brouilette, S., Shiels, P. G., Packard, C., Moore, J., Samani, N. J., & Ford, I. (2009) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2009.088427 · Cited by 58
Cui, Y. A., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.020 · Cited by 57
Beneficial Effects of Statins in Coronary Artery Disease — Beyond Lowering Cholesterol
Sotiriou, C. G., & Cheng, J. W. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.10124 · Cited by 57
In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients
Panichi, V., Paoletti, S., Mantuano, E., Manca-Rizza, G., Filippi, C., Santi, S., Taccola, D., Donadio, C., Tramonti, G., Innocenti, M., et al. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi224 · Cited by 57
Role of oxidized low-density lipoprotein in the atherosclerosis of uremia
Drüeke, T. B., Nguyen‐Khoa, T., Massy, Z. A., Witko‐Sarsat, V., Lacour, B., & Descamps‐Latscha, B. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.59780114.x · Cited by 55
WENGER, N. K., Lewis, S. J., Welty, F. K., Herrington, D. M., & Bittner, V. (2007) · Heart · doi:10.1136/hrt.2007.122325 · Cited by 55
Rayner, B. L., Byrne, M., & van Zyl-Smit, R. N. (1996) · PubMed · Cited by 53
Gheith, O. A. A., Sobh, M. A. K., Mohamed, K. E.-S., El-Baz, M. A., El-Husseini, F., Gazarin, S. S., Ahmed, H. A.-E.-H., Rasem, M. W., & Amer, G. M. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000065021 · Cited by 53
Lovastatin in the Treatment of Multifactorial Hyperlipidemia Associated With Proteinuria
Golper, T. A., Illingworth, D. R., Morris, C. D., & Bennett, W. M. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80038-1 · Cited by 53
Statins: effects beyond cholesterol lowering
Massy, Z. A., & Guijarro, C. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1738 · Cited by 53
Pedersen, T. R., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Holme, I., Larsen, M. L., Bendiksen, F. S., Lindahl, C., & Palmer, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.003 · Cited by 53
Holme, I., Cater, N. B., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Larsen, M. L., Lindahl, C., Pedersen, T. R., & Decrea, O. B. O. T. I. (2008) · Annals of Medicine · doi:10.1080/07853890801964955 · Cited by 53
Fassett, R. G., Coombes, J. S., Packham, D., Fairley, K. F., & Kincaid‐Smith, P. (2009) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365590903359908 · Cited by 52
for the LIPID Study Investigators, Söderberg, S., Colquhoun, D., KEECH, A. C., Yallop, J., Barnes, E. H., Pollicino, C., Simes, R. J., Tonkin, A. M., & Nestel, P. J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.224 · Cited by 52
Herman, W. H., Alexander, C. M., Cook, J. R., Boccuzzi, S. J., Musliner, T. A., Pedersen, T. R., KJEKSHUS, J. K., & Pyörälà, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1771 · Cited by 52
van Zuilen, A. D., Wetzels, J. F. M., Bots, M. L., & Blankestijn, P. J. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.3.261 · Cited by 52
Cholesterol, M. O. E. (2004) · Circulation Journal · doi:10.1253/circj.68.860 · Cited by 52
Macfarlane, P. W., & Norrie, J. D. (2006) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2006.05.003 · Cited by 51
Effect of simvastatin on kidney function loss in patients with coronary heart disease
Huskey, J. L., Lindenfeld, J. M., Cook, T. J., Targher, G., Kendrick, J., KJEKSHUS, J. K., Pedersen, T., & Chonchol, M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.11.010 · Cited by 50
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Thomason, M. J., Fuller, J., & on behalf of the CARDS Investigators (2005) · Diabetologia · doi:10.1007/s00125-005-0029-y · Cited by 50
Nanayakkara, P. W. B., Jong, J. C. K., Stehouwer, C. D. A., van Ittersum, F. J., Olthof, M. R., Kok, R. M., Blom, H. J., van Guldener, C., ter Wee, P. M., & Smulders, Y. M. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn040 · Cited by 50
Geluk, C. A., Asselbergs, F. W., Hillege, H. L., Bakker, S. J. L., de Jong, P. E., Zijlstra, F., & van Gilst, W. H. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi253 · Cited by 49
Newman, C. B., Szarek, M. J., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., DeMicco, D. A., Auster, S. B., & Fuller, J. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.029 · Cited by 49
Fassett, R. G., Robertson, I. K., GERAGHTY, D. P., Ball, M. J., & Coombes, J. S. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.04.004 · Cited by 48
Raikou, M., McGuire, A. J., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., Fuller, J., et al. (2007) · Diabetologia · doi:10.1007/s00125-006-0561-4 · Cited by 48
Johnson, C. J., Waters, D. D., DeMicco, D. A., Breazna, A., Bittner, V., Greten, H., Grundy, S. M., & LaRosa, J. C. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.023 · Cited by 48
Ruggenenti, P. L., Perna, A., Tonelli, M. A., Loriga, G., Motterlini, N., Rubis, N., Ledda, F., Rota, S., Satta, A. E., Granata, A. R. M., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03380410 · Cited by 48
Stegmayr, B. G., Brännström, M., Bucht, S., Crougneau, V., Dimény, E., Ekspong, A., Eriksson, M., Granroth, B., Gröntoft, K., Hadimeri, H., et al. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590500329304 · Cited by 47
Nora, E. D., Passaro, A., Zamboni, P., Calzoni, F., Fellin, R., & Solini, A. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345126 · Cited by 47
Deighan, C. J., CASLAKE, M. J., MCCONNELL, M., Boulton‐Jones, J. M., & Packard, C. J. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v122341 · Cited by 47
Brouwers, F. P. J., Asselbergs, F. W., Hillege, H. L., de Boer, R. A., Gansevoort, R. T., van Veldhuisen, D. J., & van Gilst, W. H. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.028 · Cited by 46
Kano, K., Nishikura, K., Yamada, Y., et al. (2003) · Clinical Nephrology · doi:10.5414/cnp60085 · Cited by 46
Lemos, P. A., Serruys, P. W. J. C., de Feyter, P. J., Mercado, N. F., Goedhart, D. M., Saia, F., Arampatzis, C. A., Soares, P. R., Ciccone, M. M., Arquati, M., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.008 · Cited by 45
Asselbergs, F. W., van Roon, A. M., Hillege, H. L., de Jong, P. E., Gans, R. O. B., Smit, A. J., & van Gilst, W. H. (2005) · Stroke · doi:10.1161/01.str.0000155731.92786.e9 · Cited by 45
Zhang, A., Vertommen, J., Gaal, L. V., & Leeuw, I. D. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01138-2 · Cited by 45
Hitman, G. A., Colhoun, H. M., Newman, C. B., Szarek, M. J., Betteridge, D. J., Durrington, P. N., Fuller, J., Livingstone, S. J., Neil, H. A. W., & on behalf of the CARDS Investigators (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02268.x · Cited by 45
Tonolo, G., Velussi, M., Brocco, E., Abaterusso, C., Carraro, A., Morgia, G., Satta, A. E., Faedda, R., Abhyankar, A., Luthman, H., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001515 · Cited by 44
Wilhelmsen, L., Pyörälä, K., Wedel, H., Cook, T., Pedersen, T., & Kjekshus, J. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2481 · Cited by 44
The PPP Project Investigators (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80259-8 · Cited by 44
Lindgren, P., Buxton, M. J., Kahan, T., Poulter, N. R., Dahlöf, B., Sever, P., Wedel, H., Jönsson, B., & ASCOT investigators (2005) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000159277.04062.59 · Cited by 43
West, M., Nestel, P. J., Kirby, A. C., Schnabel, R. B., SULLIVAN, D. R., Simes, R. J., Pollicino, C., Lubos, E., Münzel, T. F., White, H. D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn007 · Cited by 42
Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Ueda, Y., Suzuki, T., Ueda, S., Fukami, K., Okuda, S., & Yamagishi, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.07.011 · Cited by 41
Sever, P., Poulter, N. R., Dahlöf, B., & Wedel, H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328326cb1a · Cited by 40
Summers, M. J., Oliver, K. R., Coombes, J. S., & Fassett, R. G. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.183 · Cited by 39
Nanayakkara, P. W. B., Jong, J. C. K., ter Wee, P. M., Stehouwer, C. D. A., van Ittersum, F. J., Olthof, M. R., Teerlink, T., Twisk, J. W. R., van Guldener, C., & Smulders, Y. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.06.016 · Cited by 38
Gotto, A. M., Boccuzzi, S. J., Cook, J. R., Alexander, C. M., Roehm, J. B., Meyer, G. S., Clearfield, M. B., Weis, S. E., & Whitney, E. J. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01198-x · Cited by 35
the MASTERPLAN study group, van Zuilen, A. D., van der Tweel, I., Blankestijn, P. J., Bots, M. L., van Buren, M., ten Dam, M. A. G. J., Kaasjager, K. A. H., van de Ven, P. J. G., Vervoort, G., et al. (2006) · Trials · doi:10.1186/1745-6215-7-8 · Cited by 34
Sawara, Y., Takei, T., Uchida, K., Ogawa, T., Yoshida, T., Tsuchiya, K., & Nitta, K. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.1159 · Cited by 34
Mark, D. B., Knight, J. D., Cowper, P. A., Davidson-Ray, L. D., & Anstrom, K. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.032 · Cited by 34
Panichi, V., Mantuano, E., Paoletti, S., Santi, S., Rizza, G. M., Cutrupi, S., Pizzini, P., Spoto, B., Tripepi, G., & Zoccali, C. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.1.38 · Cited by 33
Lee, T., Lin, M., Tsai, C., & Chang, N. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00457.x · Cited by 33
Inflammatory predictors of mortality in the scandinavian simvastatin survival study
Crea, F., Monaco, C. G., Lanza, G. A., Maggi, E., Ginnetti, F., Cianflone, D., Niccoli, G., Cook, T. J., Bellomo, G., & KJEKSHUS, J. K. (2002) · Clinical Cardiology · doi:10.1002/clc.4960251005 · Cited by 33
Rutter, M. K., Prais, H., Charlton-Menys, V., Gittins, M., Roberts, C., Davies, R. R., Moorhouse, A., Jinadev, P., France, M. W., Wiles, P. G., et al. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03139.x · Cited by 33
Uchiyama, S., Nakaya, N., Mizuno, K., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., & Nakamura, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.002 · Cited by 32
Fassett, R. G., Ball, M. J., Robertson, I. K., GERAGHTY, D. P., & Coombes, J. S. (2008) · BMC Nephrology · doi:10.1186/1471-2369-9-4 · Cited by 32
Nakamura, T., Sugaya, T., Kawagoe, Y., Suzuki, T., Inoue, T., & Node, K. (2006) · American Journal of Nephrology · doi:10.1159/000091956 · Cited by 32
Yoshida, M., Matsuyama, Y., & Ohashi, Y. (2007) · Clinical Trials · doi:10.1177/1740774507081224 · Cited by 30
Imai, Y., Suzuki, H., Saito, T., Tsuji, I., Abe, K., & Saruta, T. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909070853 · Cited by 29
Samuelsson, O. G., Attman, P., Knight‐Gibson, C., Mulec, H., Weiss, L. G., & Alaupovic, P. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29883 · Cited by 28
Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency
Lintott, C. J., Scott, R. S., Bremer, J. M., & Shand, B. I. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80027-x · Cited by 28
Holme, I., Fayyad, R. S., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Larsen, M. L., Lindahl, C., Holdaas, H., Pedersen, T. R., et al. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02176.x · Cited by 27
Isaacsohn, J. L., Davidson, M. H., Hunninghake, D. B., Singer, R., McLain, R. W., & Black, D. M. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00872-9 · Cited by 27
Paniagua, J. A., López‐Miranda, J., Pérez‐Martínez, P., Marín, C., Vida, J. M. G., Fuentes, F., de la Puebla, R. Á. F., & Pérez‐Jiménez, F. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01703.x · Cited by 26
Safety and efficacy of atorvastatin in patients with severe renal dysfunction
Holmberg, B., Brännström, M., Bucht, B., Crougneau, V., Dimény, E., Ekspong, A., Granroth, B., Gröntoft, K., Hadimeri, H., Ingman, B., et al. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590510031255 · Cited by 24
Teramoto, T., Ohashi, Y., Nakaya, N., Yokoyama, S., Mizuno, K., Nakamura, H., & The MEGA Study Group (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0191 · Cited by 24
Physical Activity Levels in Patients with Chronic Kidney Disease Entering the LORD Trial
Fassett, R. G., Robertson, I. K., GERAGHTY, D. P., Ball, M. J., Burton, N. W., & Coombes, J. S. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181940aef · Cited by 24
Safety and Efficacy of Fluvastatin in Hyperlipidemic Patients With Chronic Renal Disease
Yasuda, G., Kuji, T., Hasegawa, K., Ogawa, N., Shimura, G., Ando, D., & Umemura, S. (2004) · Renal Failure · doi:10.1081/jdi-120039826 · Cited by 24
Lynch, A. I., Boerwinkle, E., Davis, B. R., Ford, C. E., Eckfeldt, J. H., Leiendecker‐Foster, C., & Arnett, D. K. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a8e81 · Cited by 24
Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion
Kostapanos, M. S., Milionis, H. J., Saougos, V. G., Lagos, K. G., Kostara, C. E., Bairaktari, E. T., & Elisaf, M. (2007) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248407306676 · Cited by 24
Samuelsson, O., Attman, P.-O., Knight-Gibson, C., Kron, B., Larsson, R., Mulec, H., Weiss, L., & Alaupovic, P. (2008) · Nephron · doi:10.1159/000189551 · Cited by 23
Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders
García-de-la-Puente, S., Arredondo-Garcı́a, J. L., Gutiérrez‐Castrellón, P., Bojórquez-Ochoa, A., Maya, E. R., & Pérez-Martínez, M. D. P. (2009) · Pediatric Nephrology · doi:10.1007/s00467-009-1128-7 · Cited by 22
Thomason, M. J., Colhoun, H. M., Livingstone, S. J., Mackness, M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & the CARDS Investigators (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01401.x · Cited by 22
Stewart, R., North, F. M., SHARPLES, K. J., Simes, R. J., Tonkin, A. M., & White, H. D. (2008) · PubMed · Cited by 20
Mullins, C. D., Rattinger, G. B., Kuznik, A., & Koren, M. J. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.007 · Cited by 20
Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease
Dummer, C. D., Thomé, F. S., Zingano, B. D. L., Lindoso, A., & Veronese, F. V. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.6.900 · Cited by 19
Ishikawa, T., Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., Uchiyama, S., Nakamura, H., & for the MEGA Study Group (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0095 · Cited by 19
Quality of care in patients with chronic kidney disease is determined by hospital specific factors
van Zuilen, A. D., Blankestijn, P. J., van Buren, M., ten Dam, M. A. G. J., Kaasjager, K. A. H., Ligtenberg, G., Sijpkens, Y. W. J., Sluiter, H. E., van de Ven, P. J. G., Vervoort, G., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq184 · Cited by 18
Alaupovic, P., Attman, P.-O., Knight‐Gibson, C., Mulec, H., Weiss, L. G., & Samuelsson, O. G. (2006) · Kidney International · doi:10.1038/sj.ki.5000327 · Cited by 18
Nakamura, H. (2007) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2007.02.003 · Cited by 18
Asselbergs, F. W., van der Harst, P., van Roon, A. M., Hillege, H. L., de Jong, P. E., Gans, R. O. B., Smit, A. J., & van Gilst, W. H. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.011 · Cited by 17
Scanferla, F., Toffoletto, P., Roncali, D., & Bazzato, G. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.10.868 · Cited by 17
Nestel, P. J., Baghurst, K. I., Colquhoun, D. M., Simes, R. J., Mehalski, K., White, H. D., Tonkin, A. M., Kirby, A. C., & Pollicino, C. A. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.6.1322 · Cited by 16
Long-Term Follow-up of the West of Scotland Coronary Prevention Study
DeFilippis, A. P., Bansal, S., & Blumenthal, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc076463 · Cited by 16
Lullo, L. D., Addesse, R., Comegna, C., Firmi, G., Galderisi, C., Iannacci, G. R., & Polito, P. (2005) · Advances in Therapy · doi:10.1007/bf02849954 · Cited by 15
Kostis, J. B., Breazna, A., DEEDWANIA, P. C., & LaRosa, J. C. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07851.x · Cited by 15
Tanaka, Y., Matsuyama, Y., & Ohashi, Y. (2007) · Statistics in Medicine · doi:10.1002/sim.3065 · Cited by 12
Miettinen, T. A., & Gylling, H. K. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.12.011 · Cited by 11
Parametric conditional frailty models for recurrent cardiovascular events in the lipid study
Cui, J. S., Forbes, A. B., Kirby, A. C., Marschner, I. C., Simes, J. R., West, M., & Tonkin, A. M. (2008) · Clinical Trials · doi:10.1177/1740774508098464 · Cited by 11
[Effect of pravastatin on hypercholesterolemia associated with proteinuria].
Arcas, J. L. A., Sánchez, R., Guijarro, C., Araque, A., Pulido, F., Praga, M., & Damiano, A. (1994) · PubMed · Cited by 10
Renke, M., Tylicki, L., Rutkowski, P., Neuwelt, A. J., Larczyński, W., Ziętkiewicz, M., Aleksandrowicz, E., Łysiak−Szydłowska, W., & Rutkowski, B. (2010) · Acta Biochimica Polonica · doi:10.18388/abp.2010_2442 · Cited by 9
West, M., White, H. D., Simes, R. J., Kirby, A. C., Watson, J. D. G., Anderson, N. E., Hankey, G. J., Wonders, S., Hunt, D. U., & Tonkin, A. M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200212000-00032 · Cited by 9
Baseline serum lipids and renal function in chronic kidney disease patients entering the LORD trial
Fassett, R. G., Ball, M. J., Robertson, I. K., GERAGHTY, D. P., & Coombes, J. S. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44580 · Cited by 8
Clinical Insights From the Treating to New Targets Trial
Waters, D. D. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.01.001 · Cited by 8
Paulsen, L., Matthesen, S. K., Bech, J. N., Starklint, J., & Pedersen, E. B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009350627 · Cited by 8
The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged menAppendix
West of Scotland Coronary Prevention Study Group (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00657-3 · Cited by 8
Yiğit, F., Müderrisoğlu, H., Güz, G., Bozbaş, H., Korkmaz, M. E., Ozin, M. B., & Tayfun, E. (2004) · Japanese Heart Journal · doi:10.1536/jhj.45.959 · Cited by 7
Yasuda, G., Ando, D., Hirawa, N., & Umemura, S. (2010) · Renal Failure · doi:10.3109/0886022x.2010.486493 · Cited by 6
Gæde, P., Jepsen, P. V., Parving, H., & Pedersen, O. B. (1999) · PubMed · Cited by 6
Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria
van der Harst, P., Asselbergs, F. W., Hillege, H. L., Voors, A. A., van Veldhuisen, D. J., & van Gilst, W. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.108 · Cited by 5
Effect of Pravastatin on Microalbuminuria in Patients with Non-Insulin-Dependent Diabetes Mellitus
Mori, Y., & Tsuruoka, A. (1992) · Tōnyōbyō/Tounyoubyou · Cited by 5
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Metadata
- Authors
- Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-05-31
- Issue
- 5
- Pages
- CD007784-CD007784
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2134777998
- Cited by
- 331
- References
- 309
- FWCI
- 35.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.